Aemetis, Inc. (NASDAQ:AMTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Aemetis, Inc. (NASDAQ:AMTX) has been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $12.95.

A number of brokerages have recently weighed in on AMTX. StockNews.com upgraded Aemetis to a “sell” rating in a research note on Wednesday, July 31st. Ascendiant Capital Markets cut their price objective on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Truist Financial reaffirmed a “hold” rating and set a $3.50 target price (down from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. UBS Group cut their price target on shares of Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a report on Monday, August 19th. Finally, HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Aemetis in a research report on Friday.

Institutional Investors Weigh In On Aemetis

Several large investors have recently added to or reduced their stakes in AMTX. FMR LLC raised its holdings in Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after acquiring an additional 9,137 shares during the period. SG Americas Securities LLC purchased a new stake in Aemetis during the 1st quarter worth about $60,000. Hutchinson Capital Management CA purchased a new stake in Aemetis during the 2nd quarter worth about $70,000. State Board of Administration of Florida Retirement System bought a new position in Aemetis in the 1st quarter worth about $84,000. Finally, Barclays PLC grew its holdings in Aemetis by 274.6% during the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after buying an additional 34,816 shares in the last quarter. Hedge funds and other institutional investors own 27.02% of the company’s stock.

Aemetis Trading Down 5.9 %

Shares of NASDAQ:AMTX opened at $3.83 on Friday. The stock has a market cap of $190.50 million, a PE ratio of -1.69 and a beta of 1.23. The stock’s fifty day simple moving average is $2.80 and its two-hundred day simple moving average is $3.06. Aemetis has a 1-year low of $2.10 and a 1-year high of $7.03.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. The firm had revenue of $81.44 million for the quarter, compared to the consensus estimate of $77.79 million. During the same period in the previous year, the business earned ($0.59) earnings per share. On average, sell-side analysts forecast that Aemetis will post -2.1 earnings per share for the current fiscal year.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.